Mechanisms of Exposure Therapy for OCD
Exposure therapy is the most effective treatment available for obsessive compulsive disorder, yet up to 50% of patients do not recover because the mechanisms underlying successful response are poorly understood, leading to significant variability in how clinicians conduct exposure therapy. The main purpose of this stud
| Condition(s) | Obsessive-Compulsive Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Exposure therapy is the most effective treatment available for obsessive compulsive disorder, yet up to 50% of patients do not recover because the mechanisms underlying successful response are poorly understood, leading to significant variability in how clinicians conduct exposure therapy. The main purpose of this study is to determine which target mechanisms are most critical to engage in real-world exposure sessions to produce good treatment outcomes. Adult participants (N = 400) with Obsessive Compulsive Disorder (OCD) receiving exposure therapy from two sites (McLean Hospital, San Diego State University) across the continuum of care (outpatient, partial hospital, residential) will complete baseline clinical and demographic measures as well as weekly symptom reports. The project will me |
| Who can participate | Inclusion Criteria: * Between the ages of 18-65 years old * Seeking exposure treatment at McLean Hospital OCD Institute or San Diego State University * Have a diagnosis of OCD * Able to complete study measures and treatment procedures in English Exclusion Criteria: * Acute symptoms of psychosis * Active suicidality (plan, means, intent and/or suicide attempt in past 3 months) * Presence of co-occurring symptoms that warrant higher level of care (e.g., inpatient treatment) * Presence of any medical, psychiatric, or developmental condition that would prevent patients from completing assessments or exposure exercises (e.g., non-verbal autism spectrum disorder) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Mclean Hospital |
| Locations | San Diego, California, United States; Belmont, Massachusetts, United States |
| Start date | 2024-10-16 |
| NCT ID | NCT06173752 |
| Official listing | https://clinicaltrials.gov/study/NCT06173752 |